Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI ...

An LLC model in biotech brings specific advantages, such as streamlined deal-making, IP ownership, and capital reinvestment ...

It wouldn't be accurate to say that surgeon-turned-healthcare investment banker and consultant Dr. Ali Pashazadeh traded his scalpels for spreadsheets. In fact, he still wields a scalpel quite ...

From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s ...

Clinical operations executives often grapple with the intricacies of trial planning, demanding accuracy at every phase. Anju's TA Scan, a web-based clinical intelligence tool, addresses these ...

Alicia Zhou, Ph.D., the incoming CEO at the Cancer Research Institute, talks about her plans and approach to moving a 70-year ...

The BIOSECURE Act, currently under consideration in the US Congress, has the potential to significantly disrupt the biologics contract manufacturing industry. This legislation aims to restrict US ...

Single-use (SU) systems show significant promise for antibody-drug conjugate (ADC) manufacturing. However, the use of organic solvents in the ADC process raises concerns about potential leachables ...

In three years, Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of ...